A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs IMG 7289 (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Imago BioSciences
- 19 Sep 2017 According to an Imago BioSciences media release, the first patients have been dosed in this trial.
- 16 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
- 04 May 2017 New trial record